WO2005051897A1 - Process for the preparation of tamsulosin - Google Patents

Process for the preparation of tamsulosin Download PDF

Info

Publication number
WO2005051897A1
WO2005051897A1 PCT/CA2004/001976 CA2004001976W WO2005051897A1 WO 2005051897 A1 WO2005051897 A1 WO 2005051897A1 CA 2004001976 W CA2004001976 W CA 2004001976W WO 2005051897 A1 WO2005051897 A1 WO 2005051897A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
aluminum
tamsulosin
reagent
ester
Prior art date
Application number
PCT/CA2004/001976
Other languages
French (fr)
Inventor
Hoi Lun Allan Tse
Original Assignee
Torcan Chemical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torcan Chemical Ltd. filed Critical Torcan Chemical Ltd.
Publication of WO2005051897A1 publication Critical patent/WO2005051897A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups

Definitions

  • the present invention relates to synthetic organic chemistry, specifically tamsulosin as well as pharmaceutically acceptable salts thereof and to methods for their preparation.
  • Tamsulosin is a known, commercially available drug, used in the treatment of benign prostate hypertrophy. Tamsulosin is commonly prepared as its hydrochloride salt. Chemical synthesis of an organic compound of the complexity of tamsulosin is commonly a multi-stage, complicated process, where losses of yield of intermediate products at various stages and requirements for purification of intermediates at various stages can add up to an overall process of unsatisfactory yield and consequent economic disadvantage. Various processes for its preparation are disclosed in the art. United States Patent Nos. 4,703,063 and 4,558,156 as well as counterpart
  • European Patent No. 0,034,432 all of Imai et al., describe two processes for preparing tamsulosin, one of which involves the conversion of a hydroxy substituted analogue of tamsulosin, i.e., a compound having the tamsulosin structure but having a hydroxyl substituent at a position a to the benznesulphonamide ring, by halogenation followed by either reduction or reaction with an alkali followed by hydrogen iodide; the other of which involves condensation of a benzenesulfonamide aldehyde with the appropriate substituted phenoxy amine, followed by reduction of the resulting imino product. These processes present some disadvantages.
  • a sulfonamide substituent is easily displaced from a benzene ring, so that subsequent chemical steps involving a benzenesulfonamide have to be conducted with great care if yield is not to be lost.
  • the benzenesulfonamide aldehyde compound prepared and used in these processes is an unstable oil.
  • Another significant disadvantage of these processes is that they are not stereospecific, i.e., they are not suitable for the preparation of individual optical isomers of tamsulosin. The final products require a step of optical resolution to obtain specific optical isomers.
  • 0380144 of Okada et al. describes a process for preparing tamsulosin and the like, in stereospecific form, by reaction of a benzenesulfonamide amine with predetermined stereospecificity, with a halogenated methyl phenyl ketone, specifically the bromide compound.
  • This bromide compound is problematic in terms of purification and storage.
  • Canadian Patent No. 1 ,340,332 of Koishi et al. describes an analogous coupling reaction, but using an aldehyde for coupling with the amine instead of the ketone. This process suffers from similar disadvantages.
  • the invention provides, in one aspect, a process for the preparation of (R)-5- [2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide (tamsulosin) of formula:
  • the aluminum reagent used in the coupling reaction between the ester (2A) and the amine (3) is preferably a trivalent aluminum reagent. It can be selected from diisobutyl aluminum hydride, trimethyl aluminum, triethyl aluminum, dimethyl aluminum chloride, aluminum isopropoxide and aluminum trichloride. This coupling reaction is preferably carried out in the present of an aprotic solvent. Solvents reaction such as tetrahydrofuran, methylene chloride, toluene and benzene can be used.
  • the above amide (4) is reduced with a reducing agent to form tamsulosin (5) above.
  • the ester used in the coupling reaction is obtained by reacting 2-ethoxy phenol with an alkyl halogeno acetate, in the presence of a base.
  • a base for example, 2-ethoxyphenoxy acetate is obtained by reacting 2-ethoxy phenol with methyl bromo acetate in the presence of potassium hydroxide.
  • Preferred esters are alkyl esters, more preferably alkyl esters wherein the alkyl substituent is straight or branched and has 1 to 6 carbon atoms.
  • the reduction reaction to yield tamsulosin is carried out in the presence of a metal reagent, which can be an aluminum reagent or a borane reagent.
  • the process comprises the further step of treating tamsulosin with an acid to yield a pharmaceutically acceptable salt thereof.
  • tamsulosin is treated with hydrochloric acid to yield tamsulosin hydrochloride salt.
  • the invention provides a process for the preparation of tamsulosin, which comprises: reacting 2-ethoxy phenol with methyl bromo acetate in the presence of a base to obtain methyl 2-ethoxyphenoxy acetate; coupling 2-ethoxyphenoxy acetate with (R)-5-(2-amino)propyl-2-methoxy- benzenesulfonamide in the presence of diisobutyl aluminum hydride to obtain tamsulosin amide; and subjecting tamsulosin amide to a reduction reaction in the presence of sodium bis(2-methoxyethoxy) aluminum dihydride or borane dimethylsulfide to yield tamsulosin.
  • the ester of formula 2A may be contaminated with up to about 10% of 2- ethoxy phenol.
  • FIGURE 1 is a reaction scheme illustrating the general process according to the invention
  • FIGURE 2 is a reaction scheme illustrating a preferred embodiment of the process according to the invention. While the invention will be described in conjunction with the embodiments illustrated in the reaction schemes, it will be understood that it is not intended to limit the invention to such embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims, including any reagents, steps or intermediate compounds that would be recognized as equivalent to those described herein by one skilled in the art.
  • Fig. 1 illustrates the general process according to the invention.
  • 2- Ethoxyphenol (1 ) is treated with an alkyl halogeno acetate in the presence of a base to yield an ester (2A).
  • the ester is further subjected to a coupling reaction with (R)- 5-(2-amino)propyl-2-methoxy-benzenesulfonamide (3) to yield tamsulosin amide (4).
  • the coupling reaction is carried out in an aprotic solvent, in the presence of an aluminum reagent. This reaction is easy to perform and its success is tolerant to the quality of the ester (2).
  • Tamsulosin amide (4) may be further subjected to a reduction reaction to yield tamsulosin (5), which can be further treated with an acid to yield a salt of tamsulosin (6A).
  • Tamsulosin obtained through the process according to the invention is in optically pure form. Indeed, the amine (R)-5-(2-amino)propyl-2- methoxy-benzenesulfonamide (3) used has the appropriate stereochemistry, which is transferred to the final product; no racemization occurred, either during the coupling reaction or during the reduction of tamsulosin amide.
  • the ester (2A) obtained after reaction of ethoxyphenol (1 ) with alkyl halogeno acetate can be used "as-is", without any purification for the coupling reaction.
  • Fig. 2 there is illustrated an example embodiment of the process according to the invention.
  • the ester, 2-ethoxyphenoxy acetate (2) is obtained by treating 2-ethoxyphenol (1) with methyl bromo acetate in the presence of potassium hydroxide.
  • the ester is further subjected to a coupling reaction with (R)-5-(2- amino)propyl-2-methoxy-benzenesulfonamide (3) to yield tamsulosin amide (4).
  • the coupling reaction is carried out in tetrahydrofuran, in the presence of diisobutyl aluminum hydride.
  • Tamsulosin amide (4) is further subjected to a reduction reaction, using either sodium bis(2-methoxyethoxy) aluminum dihydride or borane dimethylsulfide, to yield tamsulosin (5), which can be further treated with hydrochloric acid to yield tamsulosin hydrochloride salt (6).
  • a 500 ml three-neck, round bottom flask was charged with 6.25 ml of water and 6.55g of potassium hydroxide. The resulting mixture was gently stirred at ambient temperature to give a clear solution. The resulting mixture was further charged with 250 ml of toluene and 11.5 ml of 2-ethoxyphenol (75 g), then heated to reflux. Water distilled out of the reaction mixture was collected in the Dean-Stark trap. After 3 hours of heating, distillation of water from the reaction mixture had stopped. The reaction mixture was allowed to cool to room temperature.
  • a 500 ml three-necked, round bottom flask was charged with 15.12g of amine 3 and 76 ml of THF. With moderate stirring under nitrogen, a heavy white suspension was formed. The suspension was then cooled in an ice-water bath to 0- 5°C. With moderate stirring, 65 ml of a 1 M solution of diisobutylaluminum hydride in THF was added to the suspension at a rate such that the batch temperature was maintained at 5-10°C. After the addition was completed, the mixture was stirred at 5-10C for 5 minutes to give a light white suspension. The cooling bath was removed and the mixture was allowed to warm to 20-25°C and agitated for 1 hour at this temperature.
  • the cloudy solution was filtered and concentrated via distillation under atmospheric pressure.
  • the solution was cooled to 40-50°C and ethanol was added.
  • the resultant solution was again concentrated via distillation under atmospheric pressure to generate a heavy white suspension.
  • the heavy white suspension obtained above was cooled to 20-25°C. With moderate stirring, MTBE was charged.
  • the resultant mixture was stirred for 5 minutes and then cooled in an ice-water bath to 0-5°C. Agitation continued for another 30 minutes.
  • the white solid in the suspension was collected by suction filtration while cold. The cake was collected and dried under vacuum at 45°C for 16 hours to give 20.2 g of the amide 4 with a yield of 77%.
  • EXAMPLE 4 Formation of tamsulosin hydrochloride (6) using sodium bis(2- methoxyethoxy)aluminum hydride Toluene (60 mL) was added into a round bottom flask containing 6.33 g of 4. The resulting suspension was stirred moderately under nitrogen at 5-10°C. Excess sodium bis(2-methoxyethoxy)aluminum hydride (Red-AI, 6.5 equivalents) was slowly charged into this suspension. The reaction mixture was agitated at ambient temperature overnight (21 hours). The reaction was quenched with aqueous hydrochloric acid and the crude tamsulosin hydrochloride was isolated.
  • Red-AI sodium bis(2-methoxyethoxy)aluminum hydride

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

There is provided a process for the preparation of tamsulosin of formula 5, involving a coupling reaction in the presence of an aluminum reagent between an ester of formula 2A and (R)-5-(2-amino)propyl-2-methoxy-benzenesulfonamide of formula 3 to yield tamsulosin amide, which is then reduced to yield tamsulosin.

Description

TITLE OF THE INVENTION
PROCESS FOR THE PREPARATION OF TAMSULOSIN
FIELD OF THE INVENTION
The present invention relates to synthetic organic chemistry, specifically tamsulosin as well as pharmaceutically acceptable salts thereof and to methods for their preparation.
BACKGROUND OF THE INVENTION
(R)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2- methoxybenzenesulfonamide or tamsulosin has the following chemical formula:
Figure imgf000002_0001
Tamsulosin is a known, commercially available drug, used in the treatment of benign prostate hypertrophy. Tamsulosin is commonly prepared as its hydrochloride salt. Chemical synthesis of an organic compound of the complexity of tamsulosin is commonly a multi-stage, complicated process, where losses of yield of intermediate products at various stages and requirements for purification of intermediates at various stages can add up to an overall process of unsatisfactory yield and consequent economic disadvantage. Various processes for its preparation are disclosed in the art. United States Patent Nos. 4,703,063 and 4,558,156 as well as counterpart
European Patent No. 0,034,432, all of Imai et al., describe two processes for preparing tamsulosin, one of which involves the conversion of a hydroxy substituted analogue of tamsulosin, i.e., a compound having the tamsulosin structure but having a hydroxyl substituent at a position a to the benznesulphonamide ring, by halogenation followed by either reduction or reaction with an alkali followed by hydrogen iodide; the other of which involves condensation of a benzenesulfonamide aldehyde with the appropriate substituted phenoxy amine, followed by reduction of the resulting imino product. These processes present some disadvantages. In particular, a sulfonamide substituent is easily displaced from a benzene ring, so that subsequent chemical steps involving a benzenesulfonamide have to be conducted with great care if yield is not to be lost. Moreover, the benzenesulfonamide aldehyde compound prepared and used in these processes is an unstable oil. Another significant disadvantage of these processes is that they are not stereospecific, i.e., they are not suitable for the preparation of individual optical isomers of tamsulosin. The final products require a step of optical resolution to obtain specific optical isomers. European Patent No. 0380144 of Okada et al., describes a process for preparing tamsulosin and the like, in stereospecific form, by reaction of a benzenesulfonamide amine with predetermined stereospecificity, with a halogenated methyl phenyl ketone, specifically the bromide compound. This bromide compound, however, is problematic in terms of purification and storage. Canadian Patent No. 1 ,340,332 of Koishi et al. describes an analogous coupling reaction, but using an aldehyde for coupling with the amine instead of the ketone. This process suffers from similar disadvantages. Published PCT Application WO 02/068382 A1 of Ham et al. discloses a process for the preparation of some sulfanoyl-substituted phenethylamine derivatives including tamsulosin, which involves a coupling reaction between (R)-5- (2-amino)propyl-2-methoxy-benzenesulfonamide with an acid or a corresponding acid chloride or mixed anhydride to obtain tamsulosin amide. This coupling reaction presents the disadvantage that the acid or acid chloride or anhydride should be provided in a high purity in order to obtain a good yield for the coupling reaction; and it is known in the art that purification of such products is not always easy. It is generally known in the art that formation of amide from direct reaction between an ester and an amine is in general very difficult to achieve. Successes in such reaction have been reported in the following references: Basha, A.; Lipton, M.; Weinreb, S.M. Tetrahedron Lett. 1977, 4171-4174. Levin, J.I.; Turos, E.; Weinreb, S.M. Synth. Comm. 1982, 12, 989-993. Huang, P-Q.; Zheng, X.; Deng, X-M. Tetrahedron Lett. 2001, 42, 9039-9041. In these references, an aluminum reagent is used to activate the amine. As can be seen, the various synthetic processes of tamsulosin described in the above patents each present some disadvantages. Thus, there remains a need for a practical, economic and efficient synthesis of tamsulosin, in optically pure form.
SUMMARY OF THE INVENTION
It is thus an object of the present invention to provide an improved process for the preparation of tamsulosin, which is reasonably simple, economic and efficient. It was the surprising discovery of the inventors that although known reactions between an amine and ester to produce an amide are difficult to achieve, it is possible to form tamsulosin amide with relative ease by coupling an ester of general formula 2A below with (R)-5-(2-amino)propyl-2-methoxy-benzenesulfonamide (3), in the presence of an aluminium reagent which activates amine (3), thus facilitating the coupling reaction. The reaction functions relatively well despite the presence of the sulfonamide group on the amine. The invention provides, in one aspect, a process for the preparation of (R)-5- [2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide (tamsulosin) of formula:
Figure imgf000005_0001
and pharmaceutically acceptable salts thereof, which comprises coupling an ester of formula:
Figure imgf000005_0002
2A
with (R)-5-(2-amino)propyl-2-methoxy-benzenesulfonamide of formula:
Figure imgf000005_0003
in the presence of an aluminum reagent to yield tamsulosin amide of formula:
Figure imgf000006_0001
The aluminum reagent used in the coupling reaction between the ester (2A) and the amine (3), as outlined above, is preferably a trivalent aluminum reagent. It can be selected from diisobutyl aluminum hydride, trimethyl aluminum, triethyl aluminum, dimethyl aluminum chloride, aluminum isopropoxide and aluminum trichloride. This coupling reaction is preferably carried out in the present of an aprotic solvent. Solvents reaction such as tetrahydrofuran, methylene chloride, toluene and benzene can be used. The above amide (4) is reduced with a reducing agent to form tamsulosin (5) above. According to another aspect, the ester used in the coupling reaction is obtained by reacting 2-ethoxy phenol with an alkyl halogeno acetate, in the presence of a base. For example, methyl 2-ethoxyphenoxy acetate is obtained by reacting 2-ethoxy phenol with methyl bromo acetate in the presence of potassium hydroxide. Preferred esters are alkyl esters, more preferably alkyl esters wherein the alkyl substituent is straight or branched and has 1 to 6 carbon atoms. According to yet another aspect, the reduction reaction to yield tamsulosin is carried out in the presence of a metal reagent, which can be an aluminum reagent or a borane reagent. More preferably, sodium bis(2-methoxyethoxy) aluminum dihydride or borane dimethylsulfide can be used. According to another aspect, the process comprises the further step of treating tamsulosin with an acid to yield a pharmaceutically acceptable salt thereof. For example, tamsulosin is treated with hydrochloric acid to yield tamsulosin hydrochloride salt. According to another aspect, the invention provides a process for the preparation of tamsulosin, which comprises: reacting 2-ethoxy phenol with methyl bromo acetate in the presence of a base to obtain methyl 2-ethoxyphenoxy acetate; coupling 2-ethoxyphenoxy acetate with (R)-5-(2-amino)propyl-2-methoxy- benzenesulfonamide in the presence of diisobutyl aluminum hydride to obtain tamsulosin amide; and subjecting tamsulosin amide to a reduction reaction in the presence of sodium bis(2-methoxyethoxy) aluminum dihydride or borane dimethylsulfide to yield tamsulosin.
The ester of formula 2A may be contaminated with up to about 10% of 2- ethoxy phenol.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 is a reaction scheme illustrating the general process according to the invention; and FIGURE 2 is a reaction scheme illustrating a preferred embodiment of the process according to the invention. While the invention will be described in conjunction with the embodiments illustrated in the reaction schemes, it will be understood that it is not intended to limit the invention to such embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims, including any reagents, steps or intermediate compounds that would be recognized as equivalent to those described herein by one skilled in the art.
DETAILED DESCRIPTION OF THE INVENTION
In the following description, molecules have been given similar reference numerals as in the reaction schemes illustrated in the drawings. Fig. 1 illustrates the general process according to the invention. 2- Ethoxyphenol (1 ) is treated with an alkyl halogeno acetate in the presence of a base to yield an ester (2A). The ester is further subjected to a coupling reaction with (R)- 5-(2-amino)propyl-2-methoxy-benzenesulfonamide (3) to yield tamsulosin amide (4). The coupling reaction is carried out in an aprotic solvent, in the presence of an aluminum reagent. This reaction is easy to perform and its success is tolerant to the quality of the ester (2). Good results were obtained in a coupling reaction carried out using an ester sample contaminated with 10% of 2-ethoxyphenol. Tamsulosin amide (4) may be further subjected to a reduction reaction to yield tamsulosin (5), which can be further treated with an acid to yield a salt of tamsulosin (6A). Tamsulosin obtained through the process according to the invention is in optically pure form. Indeed, the amine (R)-5-(2-amino)propyl-2- methoxy-benzenesulfonamide (3) used has the appropriate stereochemistry, which is transferred to the final product; no racemization occurred, either during the coupling reaction or during the reduction of tamsulosin amide. The ester (2A) obtained after reaction of ethoxyphenol (1 ) with alkyl halogeno acetate can be used "as-is", without any purification for the coupling reaction. Turning to Fig. 2, there is illustrated an example embodiment of the process according to the invention. The ester, 2-ethoxyphenoxy acetate (2) is obtained by treating 2-ethoxyphenol (1) with methyl bromo acetate in the presence of potassium hydroxide. The ester is further subjected to a coupling reaction with (R)-5-(2- amino)propyl-2-methoxy-benzenesulfonamide (3) to yield tamsulosin amide (4). The coupling reaction is carried out in tetrahydrofuran, in the presence of diisobutyl aluminum hydride. Tamsulosin amide (4) is further subjected to a reduction reaction, using either sodium bis(2-methoxyethoxy) aluminum dihydride or borane dimethylsulfide, to yield tamsulosin (5), which can be further treated with hydrochloric acid to yield tamsulosin hydrochloride salt (6).
EXAMPLE 1 : Formation of methyl 2-ethoxyphenoxy acetate (2)
A 500 ml three-neck, round bottom flask was charged with 6.25 ml of water and 6.55g of potassium hydroxide. The resulting mixture was gently stirred at ambient temperature to give a clear solution. The resulting mixture was further charged with 250 ml of toluene and 11.5 ml of 2-ethoxyphenol (75 g), then heated to reflux. Water distilled out of the reaction mixture was collected in the Dean-Stark trap. After 3 hours of heating, distillation of water from the reaction mixture had stopped. The reaction mixture was allowed to cool to room temperature. A solution of 11.2 ml of methyl bromoacetate and 12.5 ml of toluene was added to the reaction vessel over a period of 10 minutes, resulting in a white suspension which was allowed to stir vigorously at room temperature for 2 hours. Then, 65 ml of water and 4.86 ml of ethylenediamine were added. The resulting biphasic mixture was stirred vigorously for 60 minutes. The mixture was transferred to a 500 ml separatory funnel and the biphasic layer was separated. The organic layer was collected and washed with diluted HCI solution, followed by water. The organic extract was filtered and the resulting solution was concentrated via atmospheric distillation. This solution of ester 2 in toluene was used "as-is" for the next reaction.
EXAMPLE 2: Formation of tamsulosin amide (4)
A 500 ml three-necked, round bottom flask was charged with 15.12g of amine 3 and 76 ml of THF. With moderate stirring under nitrogen, a heavy white suspension was formed. The suspension was then cooled in an ice-water bath to 0- 5°C. With moderate stirring, 65 ml of a 1 M solution of diisobutylaluminum hydride in THF was added to the suspension at a rate such that the batch temperature was maintained at 5-10°C. After the addition was completed, the mixture was stirred at 5-10C for 5 minutes to give a light white suspension. The cooling bath was removed and the mixture was allowed to warm to 20-25°C and agitated for 1 hour at this temperature. With moderate agitation, 13.02 g of 2 in toluene was charged into the mixture via a syringe. The resulting reaction mixture was stirred at 20-25°C for 16 hours and then cooled in an ice-water bath to 0-5°C. With vigorous agitation, HCI was charged in slowly such that the reaction temperature was maintained at 20- 25°C. A heavy white suspension was formed. The above suspension was transferred to a 1 L Erlenmeyer flask equipped with a magnetic stirring bar with the aid of CH2CI2. This mixture was stirred vigorously for 30 minutes at 20-25°C to give a biphasic solution. The layers were separated and the lower organic layer was collected and washed with water. The cloudy solution was filtered and concentrated via distillation under atmospheric pressure. The solution was cooled to 40-50°C and ethanol was added. The resultant solution was again concentrated via distillation under atmospheric pressure to generate a heavy white suspension. The heavy white suspension obtained above was cooled to 20-25°C. With moderate stirring, MTBE was charged. The resultant mixture was stirred for 5 minutes and then cooled in an ice-water bath to 0-5°C. Agitation continued for another 30 minutes. The white solid in the suspension was collected by suction filtration while cold. The cake was collected and dried under vacuum at 45°C for 16 hours to give 20.2 g of the amide 4 with a yield of 77%.
EXAMPLE 3: Formation of tamsulosin hydrochloride (6) using borane- dimethylsulfide
A 1 L, 3 necked round bottom flask equipped with a condenser, a mechanical stirrer, a thermometer and a nitrogen inlet, was charged 47.4 g of 4 with 500 mL of THF. The resulting suspension was brought to reflux. While maintained at reflux, the reaction solution was charged slowly and carefully with borane-dimethylsulfide (63.8 mL). The reaction mixture was continued with the reflux for 5 hours at which point the reaction was usually seen complete by HPLC. Next, the mixture was cooled to room temperature and concentrated to dryness to give a thick pale yellow oil. To this oil, methanol (300 mL) and 7 M ethanol/HCI solution (100 mL) were added and the resulting white suspension was refluxed for 0.5 hour. Then, the mixture was evaporated to dryness to give white solid. The solid was dissolved in refluxing methanol (300 mL) and then, cooled to room temperature. Diethyl ether (500 mL) was added and the suspension was stirred at room temperature for a period of 2 hours. The solid was filtered and washed with cold MeOH/diethyl ether solution (1 :3, 80 mL). The white solid was vacuum dried at 40°C overnight to give 44 g of the product (6) (92% yield).
EXAMPLE 4: Formation of tamsulosin hydrochloride (6) using sodium bis(2- methoxyethoxy)aluminum hydride Toluene (60 mL) was added into a round bottom flask containing 6.33 g of 4. The resulting suspension was stirred moderately under nitrogen at 5-10°C. Excess sodium bis(2-methoxyethoxy)aluminum hydride (Red-AI, 6.5 equivalents) was slowly charged into this suspension. The reaction mixture was agitated at ambient temperature overnight (21 hours). The reaction was quenched with aqueous hydrochloric acid and the crude tamsulosin hydrochloride was isolated. Purification of the crude product was accomplished by the liberation of the free base from the crude HCI salt with sodium hydroxide and then the extraction of the amine into dichloromethane followed by the regeneration of the salt with HCI in ether. This material was further purification by recrystallisation from methanol. The final product was isolated as a crystalline white powder in 71 % yield (4.75 g). The present invention has been described in part by reference to detailed descriptions of preferred embodiments. However, this invention is not limited to these examples but rather it extends departures and variations of the described embodiments including to the full scope of the appended claims including the chemical equivalents of aspects defined therein.

Claims

CLAIMS:
1. A process for the preparation of (R)-5-[2-[[2-(2- ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide (tamsulosin) of formula:
Figure imgf000012_0001
and pharmaceutically acceptable salts thereof, which comprises coupling an ester of formula:
2A
wherein R is alkyl, with (R)-5-(2-amino)propyl-2-methoxy-benzenesulfonamide of formula:
Figure imgf000012_0003
in the presence of an aluminum reagent to yield tamsulosin amide of formula:
Figure imgf000013_0001
followed by reduction of said amide 4 to yield tamsulosin of formula 5.
2. A process according to claim 1 , wherein R is a Ci to C& straight or branched alkyl.
3. A process according to claim 2, wherein R is CH3.
4. A process according to claim 1 , wherein said aluminum reagent is a trivalent aluminum reagent.
5. A process according to claim 1 , wherein said aluminum reagent is selected from the group consisting of diisobutyl aluminum hydride, trimethyl aluminum, triethyl aluminum, dimethyl aluminum chloride, aluminum isopropoxide and aluminum trichloride.
6. A process according to claim 1 , wherein said coupling is carried out in an aprotic solvent.
7. A process according to claim 6, wherein said solvent is selected from the group consisting of tetrahydrofuran, methylene chloride, toluene and benzene.
8. A process according to claim 1 , wherein said ester is obtained by reacting 2- ethoxy phenol with an alkyl halogeno acetate, in the presence of a base.
9. A process according to claim 3, wherein said ester of formula 2 is obtained by reacting 2-ethoxy phenol with methyl bromo acetate in the presence of a base.
10. A process according to claim 1 , wherein said reduction of the amide is carried out in the presence of a metal reagent.
11. A process according to claim 10, wherein said metal reagent is selected from aluminum reagent and borane reagent.
12. A process according to claim 10, wherein said metal reagent is selected from the group consisting of sodium bis(2-methoxyethoxy) aluminum dihydride and borane dimethylsulfide.
13. A process according to claim 1 , wherein said ester has a purity of about 90% or higher.
14. A process according to claim 13, wherein said ester is contaminated with up to 10% of 2-ethoxy phenol.
15. A process for the preparation of tamsulosin, which comprises: reacting 2-ethoxy phenol with an alkyl halogeno acetate in the presence of a base to obtain an ester; coupling the ester with (R)-5-(2-amino)propyl-2-methoxy-benzene- sulfonamide in the presence of an aluminum reagent to obtain tamsulosin amide; and subjecting tamsulosin amide to a reduction reaction in the presence of a metal reagent to yield tamsulosin.
16. A process according to claim 15, wherein said alkyl halogeno acetate is methyl bromo acetate and said ester is methyl 2-ethoxyphenoxy acetate.
17. A process according to claim 15, wherein said aluminum reagent is diisobutyl aluminum hydride.
18. A process according to claim 15, wherein said metal reagent is selected from the group consisting of sodium bis(2-methoxyethoxy) aluminum dihydride and borane dimethylsulfide.
19. A process according to claim 15 further comprising the step of treating tamsulosin with an acid to yield a pharmaceutically acceptable salt thereof.
20. A process according to claim 15, wherein said alkyl halogen acetate is a Ci to CQ straight or branched alkyl halogeno acetate.
21. Tamsulosin produced by a process defined in any of claims 1 to 19.
22. A process for preparing tamsulosin amide of formula 4:
Figure imgf000015_0001
comprising coupling an ester of formula 2A:
Figure imgf000015_0002
2A wherein R is alkyl, with (R)-5-(2-amino)propyl-2-methoxy-benzenesulfonamide of formula:
Figure imgf000016_0001
in the presence of an aluminum reagent to yield tamsulosin amide of formula:
Figure imgf000016_0002
followed by reduction of said amide 4 to yield tamsulosin of formula 5.
23. A process according to claim 22, wherein R is a Ci to CQ straight or branched alkyl.
24. A process according to claim 23, wherein R is CH3.
25. A process according to claim 22, wherein said aluminum reagent is a trivalent aluminum reagent.
26. A process according to claim 22, wherein said aluminum reagent is selected from the group consisting of diisobutyl aluminum hydride, trimethyl aluminum, triethyl aluminum, dimethyl aluminum chloride, aluminum isopropoxide and aluminum trichloride.
27. A process according to claim 22, wherein said coupling is carried out in an aprotic solvent.
28. A process according to claim 27, wherein said solvent is selected from the group consisting of tetrahydrofuran, methylene chloride, toluene and benzene.
29. A process according to claim 22, wherein said ester is obtained by reacting 2- ethoxy phenol with an alkyl halogeno acetate, in the presence of a base.
30. A process according to claim 24, wherein said ester of formula 2 is obtained by reacting 2-ethoxy phenol with methyl bromo acetate in the presence of a base.
31. A process according to claim 22, wherein said reduction of the amide is carried out in the presence of a metal reagent.
32. A process according to claim 31 , wherein said metal reagent is selected from aluminum reagent and borane reagent.
33. A process according to claim 31 , wherein said metal reagent is selected from the group consisting of sodium bis(2-methoxyethoxy) aluminum dihydride and borane dimethylsulfide.
34. A process according to claim 22, wherein said ester has a purity of about 90% or higher.
35. A process according to claim 34, wherein said ester is contaminated with up to 10% of 2-ethoxy phenol.
36. A process for the preparation of tamsulosin, which comprises: reacting 2-ethoxy phenol with an alkyl halogeno acetate in the presence of a base to obtain an ester; coupling the ester with (R)-5-(2-amino)propyl-2-methoxy-benzene- sulfonamide in the presence of an aluminum reagent to obtain tamsulosin amide; and subjecting tamsulosin amide to a reduction reaction in the presence of a metal reagent to yield tamsulosin.
37. A process according to claim 36, wherein said alkyl halogeno acetate is methyl bromo acetate and said ester is methyl 2-ethoxyphenoxy acetate.
38. A process according to claim 36, wherein said aluminum reagent is diisobutyl aluminum hydride.
39. A process according to claim 36, wherein said metal reagent is selected from the group consisting of sodium bis(2-methoxyethoxy) aluminum dihydride and borane dimethylsulfide.
40. A process according to claim 36, wherein said alkyl halogen acetate is a d to Cβ straight or branched alkyl halogeno acetate.
PCT/CA2004/001976 2003-11-26 2004-11-16 Process for the preparation of tamsulosin WO2005051897A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2451175 CA2451175A1 (en) 2003-11-26 2003-11-26 Process for the preparation of tamsulosin
CA2,451,175 2003-11-26

Publications (1)

Publication Number Publication Date
WO2005051897A1 true WO2005051897A1 (en) 2005-06-09

Family

ID=34596843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/001976 WO2005051897A1 (en) 2003-11-26 2004-11-16 Process for the preparation of tamsulosin

Country Status (3)

Country Link
AR (1) AR046661A1 (en)
CA (1) CA2451175A1 (en)
WO (1) WO2005051897A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070285A2 (en) * 2004-12-31 2006-07-06 Quimica Sintetica, S.A. Enzymatic preparation of an intermediate compound for the synthesis of tamsulosin
WO2007086074A2 (en) * 2006-01-27 2007-08-02 Usv Limited A process for the preparation of r (-) tamsulosin hydrochloride
JP2008526904A (en) * 2005-01-14 2008-07-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Hydroxyphenol derivatives, methods for their preparation, pharmaceutical compositions containing them, and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731478A (en) * 1980-02-08 1988-03-15 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives, their preparation, and pharmaceutical compositions, containing them
WO2002068382A1 (en) * 2001-02-23 2002-09-06 Yonsung Fine Chemical Co. Ltd. Process for preparing sulfamoyl-substituted phenethylamine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731478A (en) * 1980-02-08 1988-03-15 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives, their preparation, and pharmaceutical compositions, containing them
WO2002068382A1 (en) * 2001-02-23 2002-09-06 Yonsung Fine Chemical Co. Ltd. Process for preparing sulfamoyl-substituted phenethylamine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG ET AL.: "DIBAL-H-H2NR and BIBAL-H-HNR1R2HCl complexes for efficient conversion of lactones and esters to amides", TETRAHEDRON LETTERS, vol. 42, no. 51, 17 December 2001 (2001-12-17), pages 9039 - 9041, XP004323312, DOI: doi:10.1016/S0040-4039(01)01933-5 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070285A2 (en) * 2004-12-31 2006-07-06 Quimica Sintetica, S.A. Enzymatic preparation of an intermediate compound for the synthesis of tamsulosin
WO2006070285A3 (en) * 2004-12-31 2006-08-31 Sint Quimica Sa Enzymatic preparation of an intermediate compound for the synthesis of tamsulosin
JP2008526904A (en) * 2005-01-14 2008-07-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Hydroxyphenol derivatives, methods for their preparation, pharmaceutical compositions containing them, and therapeutic uses thereof
WO2007086074A2 (en) * 2006-01-27 2007-08-02 Usv Limited A process for the preparation of r (-) tamsulosin hydrochloride
WO2007086074A3 (en) * 2006-01-27 2008-05-02 Usv Ltd A process for the preparation of r (-) tamsulosin hydrochloride

Also Published As

Publication number Publication date
AR046661A1 (en) 2005-12-14
CA2451175A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
CN114057712A (en) Method for synthesizing chiral phenyl oxazolidine-2-ketone
CN105017099B (en) Sitagliptin chiral intermediate and asymmetric synthesis method thereof
WO2005051897A1 (en) Process for the preparation of tamsulosin
EP3728167B1 (en) A process for the preparation of crisaborole
KR20080031910A (en) Process for the preparation of 1-[cyano(4-hydroxyphenyl)methyl]cyclohexanol compounds
JP7553928B2 (en) Biliverdin compounds, their production method and use
JP4029992B2 (en) Production of tartranic acid
WO2000015625A2 (en) Methods of making dihydropyrone hiv protease inhibitors
JP4255249B2 (en) Salt of optically active amino alcohol easily recovered and reused, and method for producing optically active alcohol using the salt
JP2001302658A (en) Method for manufacturing of 3-isochromanones
JP3779452B2 (en) Method for producing alcohols
EP0687683B1 (en) Process for the synthesis of haloalkylferrocenes
WO2008115912A1 (en) Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
JPH0667942B2 (en) Tetrahydro tricyclic compound
JP2804654B2 (en) Method for producing (S)-(-)-dehydro-α-damaschol
JP2000063321A (en) Production of long-chain beta-hydroxycarboxylic acid of high optical purity
WO2023082149A1 (en) Process and intermediates for preparation of isofetamid
JP2002512210A (en) Method for producing 2-hydroxyalkylhalophenone
JP2737304B2 (en) Chiral ferrocene derivatives
JP3041999B2 (en) Method for producing optically active glycerol ester
JP3371009B2 (en) Method for producing carboxylic acid derivative
EP0354078A2 (en) Derivatives of benzocycloheptene, method for their preparation and pharmaceutical compositions containing same
FR2777278A1 (en) Production of 3-hydroxymethyl-quinuclidine useful as intermediate for antihistamine mequitazine
JPS6213935B2 (en)
JP2001131101A (en) Method for producing optically active alcohol compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase